COBRA combination therapy in daily practice--getting back to the future.
Boers
M
M
D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D012219:Rheumatology / Q000379:methods*; D000069283:Rituximab; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D012460:Sulfasalazine; D000069283:Rituximab; D000069594:Abatacept; D011239:Prednisolone; D008727:Methotrexate